MILAN, October 7, 2025 — AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, announced three presentations at the European Society of Gene & Cell Therapy 32nd Annual Meeting (ESGCT), to be held October 7-10 in Seville (Spain).
At this conference, we will be presenting LUCE Phase 1/2 clinical data from our Usher1B program, KO pig model preclinical data from our Stargardt’s program and the platform development of a dual vector AAV therapy to enable the clinical supply for our programs. In addition, our Founder and Chief Scientific officer, Professor Alberto Auricchio, TIGEM Scientific Director and ESGCT president, will give the presidential address during the Presidential symposium session.
Presentations details:
Presentation Date/Time: Thursday 9 October 2025, 18.30-19.00 h CEST
Session title: Late breaking news from the clinic
Session Room: Room Parallel D
Abstract number: INV71
Presentation title: “LUCE: Phase I/II trial of dual AAV gene therapy for Retinitis Pigmentosa in Usher Syndrome Type 1B”
Presentation Date/Time: Thursday 9 October 2025, 12.35-13.00 h CEST
Session title: Presidential symposium
Session Room: Auditorium
Abstract number: OR066
Presentation title: “Advancing AAV-based gene therapy for inherited retinal disorders due to mutations in large genes”
Presentation Date/Time: Thursday 9 October 2025, 14.00-15.30 h CEST
Session title: Poster Session 2
Session Room: Poster Hall
Final abstract number: P0122
Presentation title: “Platform development for a dual AAV therapy”